Jeil MG Injection (Magnesium Sulfate Heptahydrate)

Adult administration

Hypomagnesemia-related convulsions: 1 to 2 g of magnesium sulfate administered intravenously (4.05 to 8.1 mmol). Eclamptic seizures: 4 to 5 g of this medication administered intravenously over 10 minutes (16.2 to 20.25 mmol). Prevention of uterine contractions: initially 4 g of this medication administered intravenously (16.2 mmol). Subsequently, 1 g may be given. Electrolyte replenishment (hypomagnesemia):

Child administration

The safety of this medication has not been tested.

This medication is in injectable form and may introduce glass particles upon opening the container, so extreme caution is required during use. Particularly when used in children or the elderly, greater care must be taken. This medication should not be used in patients with poor renal function, patients who are unconscious, patients with high serum magnesium levels, patients with issues in cardiac electrical signal transmission, and patients with muscle weakness. Care should be taken when using this medication in children with gastrointestinal parasitic diseases or patients with heart conditions. The use of this medication may result in a slow heart rate or issues with electrical signal transmission in the heart, and high doses may cause excessive accumulation of magnesium in the body leading to heat sensation, thirst, low blood pressure, central nervous system depression, decreased heart rate, and respiratory distress. In such cases, calcium can be administered intravenously to neutralize. Additionally, peripheral blood vessels may dilate affecting blood circulation. Caution is necessary when using this medication with other drugs. When used with central nervous system depressants, the effect may be enhanced, requiring dose adjustments. Use with iron supplements, certain antibiotics, and sodium fluoride may decrease the absorption of these medications. Absorption changes may also occur when used with isoniazid, chlorpromazine, and digoxin. This medication may be used during pregnancy for the treatment of eclampsia; however, it may affect the fetus causing muscle tone reduction, diminished reflexes, and low blood pressure, so fetal status must be closely monitored. It should not be used within 2 hours after delivery as it may cause respiratory depression in the newborn. Prolonged or repeated use may lead to skeletal abnormalities or changes in calcium levels in the fetus, so the condition of the newborn should be closely observed. Safety during breastfeeding has not been established, so it is advisable not to use it unless absolutely necessary. Elderly patients may have reduced physical function, so administration rates should be slowed and doses reduced with caution. When this medication is administered intravenously as a standalone treatment, it should be slowly infused at a concentration below 10%, and specific medications should not be mixed as it may cause precipitation. When used for electrolyte correction, it must be diluted and any remaining medication after opening should not be reused, and the patient's skin and the apparatus should be properly disinfected before use.

Serious side effects

Respiratory paralysis

Mild side effects

• Conduction disturbances
• bradycardia
• heat sensation
• thirst
• low blood pressure
• central nervous system depression
• reduced heart rate
• peripheral vascular dilation

This medication should be stored in a sealed container to avoid contact with air and kept at room temperature between 1 and 30 degrees Celsius. Proper storage helps maintain the medication's effectiveness and safety.

Appearance

Colorless solution in a colorless ampoule

Package unit

5 mL/ampoule x 25 ampoules